iA Global Asset Management Inc. Raises Stock Position in Gilead Sciences, Inc. $GILD

iA Global Asset Management Inc. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 221,890 shares of the biopharmaceutical company’s stock after acquiring an additional 23,046 shares during the period. iA Global Asset Management Inc.’s holdings in Gilead Sciences were worth $24,630,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Gilead Sciences in the 2nd quarter worth $2,150,268,000. Ameriprise Financial Inc. lifted its stake in Gilead Sciences by 397.6% in the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after acquiring an additional 5,392,191 shares during the period. Invesco Ltd. lifted its stake in Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after acquiring an additional 3,394,330 shares during the period. Assenagon Asset Management S.A. grew its holdings in Gilead Sciences by 164.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after acquiring an additional 2,169,266 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the transaction, the chief executive officer owned 566,698 shares in the company, valued at approximately $70,740,911.34. This represents a 1.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 141,757 shares of company stock worth $17,569,112 in the last 90 days. 0.27% of the stock is owned by insiders.

Analyst Ratings Changes

GILD has been the topic of a number of recent research reports. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. UBS Group reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Thursday, January 15th. Wells Fargo & Company lifted their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Royal Bank Of Canada upped their price objective on Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a research note on Tuesday. Finally, Morgan Stanley dropped their price objective on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $133.52.

Gilead Sciences Stock Up 1.6%

Gilead Sciences stock opened at $131.14 on Friday. Gilead Sciences, Inc. has a 1-year low of $92.21 and a 1-year high of $133.10. The business has a fifty day moving average price of $123.76 and a 200-day moving average price of $118.46. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The stock has a market capitalization of $162.70 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 0.68 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm’s revenue was up 3.0% compared to the same quarter last year. During the same period last year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: NEJM published full Phase 3 ASCENT‑04/KEYNOTE‑D19 results showing Trodelvy (sacituzumab govitecan) + Keytruda met the primary endpoint with a ~35% PFS improvement (HR 0.65), supporting the combo as a potential new first‑line standard in PD‑L1+ metastatic TNBC — a major commercial catalyst for Gilead’s oncology franchise. NEJM ASCENT-04 Results
• Positive Sentiment: Multiple outlets (PharmaLetter) summarized the NEJM publication and reinforced the significance of the clinical data for Trodelvy’s uptake and reimbursement discussions — amplifying the immediate market reaction. PharmaLetter Trodelvy-Keytruda NEJM Coverage
• Positive Sentiment: Rothschild & Co Redburn raised its price target to $159 and kept a “buy” rating — a bullish institutional signal that supports further upside and likely contributed to buying momentum. Rothschild & Co Redburn Price Target
• Positive Sentiment: Investor commentary highlighting margin expansion and stronger free cash flow as underappreciated drivers has supported fundamental buying beyond the clinical news. Seeking Alpha on Margins & Cash Flow
• Neutral Sentiment: Market write‑ups and a Zacks note pointed out that GILD outpaced the broader market today — useful for context but largely descriptive of price action rather than new fundamental change. Zacks: Why GILD Outpaced Market
• Neutral Sentiment: Valuation and technical pieces note recent share‑price strength and improved momentum — these can attract traders but don’t alter the clinical/commercial thesis. Yahoo Valuation Check
• Negative Sentiment: Director Jeffrey Bluestone sold 5,000 shares (~$617.5k at ~$123.50), reducing his stake by ~36% — an insider sale that can prompt short‑term investor concern about timing or confidence (though insiders sell for many non‑signal reasons). SEC Form 4 — Bluestone
• Negative Sentiment: RBC’s price target (~$103, sector perform) remains well below current levels — a conservative analyst view that could limit upside if other firms adopt similar stances. RBC Price Target Note

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.